.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The GBM AGILE trial recently released critical survival results for Regorafenib for Glioblastoma. Initially, earlier phase studies suggested potential benefits for this multikinase inhibitor in treating brain tumors. However, this large-scale registration trial failed to confirm survival advantages in newly diagnosed or recurrent settings. Consequently, these findings significantly impact how clinicians approach therapy for aggressive gliomas.
Specifically, the trial enrolled patients with newly diagnosed unmethylated (NDU) and recurrent disease (RD). Participants received regorafenib or standard-of-care controls like temozolomide or lomustine. Furthermore, the statistical analysis utilized a Bayesian adaptive design to monitor efficacy closely. Unfortunately, the results showed median overall survival (OS) did not improve with regorafenib. For example, OS was 12.0 months in NDU patients compared to 13.7 months in the control group. Similarly, RD patients saw 8.0 months with regorafenib versus 9.2 months with lomustine.
Moreover, researchers noted increased toxicity levels in the regorafenib arm relative to the control arms. Because of these results, the drug did not meet the predefined criteria for superiority. Therefore, oncology guidelines have started removing regorafenib as a recommended option for recurrent glioblastoma. In summary, while the platform effectively tested the drug, regorafenib provides no survival benefit for these patients.
The trial found that regorafenib did not improve overall survival in patients with either newly diagnosed unmethylated or recurrent glioblastoma when compared to standard treatments.
Notably, the regorafenib arm was associated with increased toxicity compared to the control treatments, which included temozolomide and lomustine.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Wen PY et al. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026 Apr 14. doi: 10.1200/JCO-25-01137. PMID: 41980234.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The GBM AGILE trial found that regorafenib did not improve overall survival in newly diagnosed or recurrent glioblastoma, leading to its removal from guidel...
3 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
